Loading...
Market
Story
FDA Approves Pfizer's Once-Weekly HYMPAVZI for Hemophilia Treatment
Oct 11, 2024, 05:39 PM
The U.S. Food and Drug Administration (FDA) has approved Pfizer's HYMPAVZI™ (marstacimab-hncq) for the treatment of adults and adolescents with Hemophilia A or B without inhibitors. This approval marks the first once-weekly injection available for the two main types of this rare bleeding disorder. Hemophilia is a potentially deadly genetic condition that prevents blood from clotting properly. Pfizer's stock symbol is $PFE.
View original story
Similar markets
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
16+ countries • 25%
Less than 5 • 25%
5 to 10 • 25%
11 to 15 • 25%
More than 15 • 25%
Low (<10%) • 25%
Moderate (10-30%) • 25%
High (30-50%) • 25%
Very High (>50%) • 25%
Less than 5 • 25%
5 to 10 • 25%
11 to 20 • 25%
More than 20 • 25%
Less than 5 countries • 25%
5 to 10 countries • 25%
11 to 20 countries • 25%
More than 20 countries • 25%
Yes • 50%
No • 50%
1-3 countries • 25%
4-6 countries • 25%
7-9 countries • 25%
10 or more countries • 25%
Less than 5 • 33%
5 to 10 • 34%
More than 10 • 33%